Greg Luerman's Biography

Greg Luerman, Technical Director, Axiogenesis AG

Dr. Greg Luerman is the Technical Director for Axiogenesis (North America). Following his graduate studies at the University of Louisville School of Medicine, Dr. Luerman earned a Michael J Fox Foundation postdoctoral fellowship within the Pfizer Neuroscience Research Unit. There he was the biology project lead on a small molecule kinase project. He moved on to establish multiple iPS-cardiomyocyte ion channel preclinical safety/tox and drug discovery services at ChanTest Corp. Now at Axiogenesis, Dr. Luerman oversees North American scientific project development, applications support, assay services, and regulatory body interactions.

Quality Control: Driving Standardization For Commercially-Available iPSC-derived Cell Types

Tuesday, 11 July 2017 at 10:30

Add to Calendar ▼2017-07-11 10:30:002017-07-11 11:30:00Europe/LondonQuality Control: Driving Standardization For Commercially-Available iPSC-derived Cell TypesStem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Stem cell technologies have revolutionized our industry. In addition to humanizing drug discovery, these differentiated tissues now closely mirror the existing biology and physiology of an adult tissue system. This provides an ideal system for drug toxicity testing, disease modeling, and efficacy screening. For these cells to see further adoption into the industry, tight quality control metrics must be in place to guarantee reproducible results. Axiogenesis is helping to drive the establishment of industry-wide QC standards for iPS cell products.

Add to Calendar ▼2017-07-10 00:00:002017-07-11 00:00:00Europe/LondonStem Cells for Drug Discovery and Toxicity Screening 2017Stem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors